340 related articles for article (PubMed ID: 30703432)
1. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases.
Cheng Y; Ma XL; Wei YQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):289-312. PubMed ID: 30703432
[TBL] [Abstract][Full Text] [Related]
2. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer.
Ji HZ; Liu B; Ren M; Li S; Zheng JF; Liu TY; Yu HH; Sun Y
Expert Rev Clin Immunol; 2024 May; 20(5):559-569. PubMed ID: 38224014
[TBL] [Abstract][Full Text] [Related]
3. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.
Sano M; Ijichi H; Takahashi R; Miyabayashi K; Fujiwara H; Yamada T; Kato H; Nakatsuka T; Tanaka Y; Tateishi K; Morishita Y; Moses HL; Isayama H; Koike K
Oncogenesis; 2019 Jan; 8(2):8. PubMed ID: 30659170
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.
Cheng Y; Mo F; Li Q; Han X; Shi H; Chen S; Wei Y; Wei X
Mol Cancer; 2021 Apr; 20(1):62. PubMed ID: 33814009
[TBL] [Abstract][Full Text] [Related]
5. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
6. Host Cxcr2-dependent regulation of mammary tumor growth and metastasis.
Sharma B; Nannuru KC; Varney ML; Singh RK
Clin Exp Metastasis; 2015 Jan; 32(1):65-72. PubMed ID: 25511644
[TBL] [Abstract][Full Text] [Related]
7. Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis.
Wu X; Xia J; Wang Z; Xu Z; Liu K; Fu X; Deng H
J Ethnopharmacol; 2022 Sep; 295():115277. PubMed ID: 35427725
[TBL] [Abstract][Full Text] [Related]
8. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
9. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.
Zhang W; Wang H; Sun M; Deng X; Wu X; Ma Y; Li M; Shuoa SM; You Q; Miao L
Cancer Commun (Lond); 2020 Mar; 40(2-3):69-80. PubMed ID: 32237072
[TBL] [Abstract][Full Text] [Related]
10. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
11. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Ha H; Debnath B; Neamati N
Theranostics; 2017; 7(6):1543-1588. PubMed ID: 28529637
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory chemokines and metastasis--tracing the accessory.
Borsig L; Wolf MJ; Roblek M; Lorentzen A; Heikenwalder M
Oncogene; 2014 Jun; 33(25):3217-24. PubMed ID: 23851506
[TBL] [Abstract][Full Text] [Related]
13. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.
Boppana NB; Devarajan A; Gopal K; Barathan M; Bakar SA; Shankar EM; Ebrahim AS; Farooq SM
Exp Biol Med (Maywood); 2014 May; 239(5):509-18. PubMed ID: 24625439
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma.
Kasashima H; Yashiro M; Nakamae H; Masuda G; Kinoshita H; Morisaki T; Fukuoka T; Hasegawa T; Nakane T; Hino M; Hirakawa K; Ohira M
PLoS One; 2017; 12(6):e0178635. PubMed ID: 28575019
[TBL] [Abstract][Full Text] [Related]
15. The CXCL8-CXCR1/2 pathways in cancer.
Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
[TBL] [Abstract][Full Text] [Related]
16. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
17. CXCR2-Mediated Granulocytic Myeloid-Derived Suppressor Cells' Functional Characterization and Their Role in Maternal Fetal Interface.
Kang X; Zhang X; Liu Z; Xu H; Wang T; He L; Zhao A
DNA Cell Biol; 2016 Jul; 35(7):358-65. PubMed ID: 27027573
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Benzocyclic Sulfone Derivatives as Potent CXCR2 Antagonists for Cancer Immunotherapy.
Dong Y; Fu R; Chen J; Zhang K; Ji M; Wang M; Jiang H; Ye W; Hu J; Li Y; Jin J; Chen X; Xu H
J Med Chem; 2021 Nov; 64(22):16626-16640. PubMed ID: 34676759
[TBL] [Abstract][Full Text] [Related]
19. Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis.
Purohit A; Saxena S; Varney M; Prajapati DR; Kozel JA; Lazenby A; Singh RK
Am J Pathol; 2021 Apr; 191(4):759-771. PubMed ID: 33453178
[TBL] [Abstract][Full Text] [Related]
20. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers.
Xie Y; Kuang W; Wang D; Yuan K; Yang P
Eur J Med Chem; 2023 Mar; 250():115175. PubMed ID: 36780833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
